1088434-86-9 Usage
Biological Activity
acs 67 is an analog of latanoprost acid.latanoprost, an f-series prostaglandin (pg) analog, has been approved for use as an ocular hypotensive drug for the treatment of glaucoma clinically. latanoprost is an isopropyl ester, a prodrug form which is converted to free latanoprost acid by endogenous esterase enzymes.
in vitro
in previous study, acs 67 was found to be able to increase the reduced glutathione levels in normotensive pigmented rabbits significantly after single administration in a dose-dependent manner. furthermore, in glaucomatous pigmented rabbits after repeated 5-day administration, acs 67 could also increase the gsh levels when compared with latanoprost. in addition, it was found that acs 67 could significantly increase the cgmp levels in glaucomatous pigmented rabbits and these data with the combination supported that the increase of cgmp was due to the sulfurated moiety of acs 67. moreover, the tolerability was measured in new zealand albino rabbits at three different concentrations of acs 67, and results indicated that acs 67 was very well tolerated in draize test [1].
references
[1] e. perrino, c. uliva, c. lanzi, et al. new prostaglandin derivative for glaucoma treatment. bioorganic & medicinal chemistry letters 19, 1639-1642 (2009).
Check Digit Verification of cas no
The CAS Registry Mumber 1088434-86-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,8,8,4,3 and 4 respectively; the second part has 2 digits, 8 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1088434-86:
(9*1)+(8*0)+(7*8)+(6*8)+(5*4)+(4*3)+(3*4)+(2*8)+(1*6)=179
179 % 10 = 9
So 1088434-86-9 is a valid CAS Registry Number.
1088434-86-9Relevant articles and documents
New prostaglandin derivative for glaucoma treatment
Perrino, Elena,Uliva, Caterina,Lanzi, Cecilia,Soldato, Piero Del,Masini, Emanuela,Sparatore, Anna
, p. 1639 - 1642 (2009)
A hydrogen sulphide-releasing derivative of latanoprost acid (ACS 67) was synthesized and tested in vivo to evaluate its activity on reduction of intraocular pressure and tolerability. Glutathione (GSH) and cGMP content were also measured in the aqueous h
PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS
-
, (2009/01/20)
The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension.
